Vigonvita Life Sciences Co (HKSE:02630) Enterprise Value: HK$14,459.2 Mil (As of Jul. 28, 2026) ***

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02630 Vigonvita Life Sciences Co Ltd HKSE:02630
8 GF Score
Price HK$90.00
! 2 Warning Signs
View Full Analysis

What is Vigonvita Life Sciences Co Enterprise Value?

Vigonvita Life Sciences Co HKSE:02630 +5.32% 8 Enterprise Value is HK$14,459.2 Mil as of Jul. 28, 2026. GuruFocus rates HKSE:02630 with a GF Score™ of 8/100. The stock has 2 warning signs investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vigonvita Life Sciences Co's Enterprise Value is HK$14,459.2 Mil. Vigonvita Life Sciences Co does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vigonvita Life Sciences Co's EV-to-EBIT at this moment.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Vigonvita Life Sciences Co's Enterprise Value is HK$14,459.2 Mil. Vigonvita Life Sciences Co does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vigonvita Life Sciences Co's EV-to-EBITDA at this moment.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Vigonvita Life Sciences Co's Enterprise Value is HK$14,459.2 Mil. Vigonvita Life Sciences Co does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vigonvita Life Sciences Co's EV-to-Revenue at this moment.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Vigonvita Life Sciences Co's Enterprise Value is HK$14,459.2 Mil. Vigonvita Life Sciences Co does not have enough years/quarters to calculate its Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vigonvita Life Sciences Co's EV-to-OCF at this moment.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Vigonvita Life Sciences Co's Enterprise Value is HK$14,459.2 Mil. Vigonvita Life Sciences Co does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vigonvita Life Sciences Co's EV-to-FCF at this moment.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Vigonvita Life Sciences Co  (HKSE:02630) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.


Vigonvita Life Sciences Co Enterprise Value Related Terms


Vigonvita Life Sciences Co Enterprise Value Historical Data

* Premium members only.

The historical data trend for Vigonvita Life Sciences Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vigonvita Life Sciences Co Enterprise Value Chart

Vigonvita Life Sciences Co Annual Data
Trend Dec23 Dec24 Dec25
Enterprise Value
0.00 0.00 13,874.07

Vigonvita Life Sciences Co Semi-Annual Data
Dec23 Dec24 Dec25
Enterprise Value 0.00 0.00 13,874.07

HKSE:02630 vs LLY, JNJ, ABBV: Enterprise Value Comparison

For the Drug Manufacturers - General subindustry, Vigonvita Life Sciences Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vigonvita Life Sciences Co Enterprise Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vigonvita Life Sciences Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Vigonvita Life Sciences Co's Enterprise Value falls into.


HKSE:02630
8GF Score
Vigonvita Life Sciences Co Ltd HKSE:02630
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vigonvita Life Sciences Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Vigonvita Life Sciences Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as

Vigonvita Life Sciences Co's Enterprise Value for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of HK$14,459.2 Mil mean?
Vigonvita Life Sciences Co (HKSE:02630) has a Enterprise Value of HK$14,459.2 Mil as of Jul. 28, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Vigonvita Life Sciences Co and its competitors.
Is Vigonvita Life Sciences Co's Enterprise Value too high?
Vigonvita Life Sciences Co's current Enterprise Value is HK$14,459.2 Mil. Overall, Vigonvita Life Sciences Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vigonvita Life Sciences Co's Enterprise Value compare to LLY and JNJ?
Vigonvita Life Sciences Co's Enterprise Value of HK$14,459.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Vigonvita Life Sciences Co and its competitors. Vigonvita Life Sciences Co's current Enterprise Value is HK$14,459.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vigonvita Life Sciences Co stock overvalued right now?
Vigonvita Life Sciences Co (HKSE:02630) has a current Enterprise Value of HK$14,459.2 Mil. The current Enterprise Value is HK$14,459.2 Mil. Vigonvita Life Sciences Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Vigonvita Life Sciences Co (HKSE:02630), the current Enterprise Value is HK$14,459.2 Mil as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vigonvita Life Sciences Co Business Description

Address No. 108, Yuxin Road, 8th Floor, Building A, Suzhou Industrial Park District, Suzhou, CHN, 215123
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
8GF Score

Get the complete analysis for HKSE:02630

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$90.00
Price